You are now leaving our website and heading to a third-party website that we do not operate. We are not responsible for the content of the third-party website. You are advised to review its privacy policy as it may differ from ours.
Are you sure you want to leave?
Cancel
Join our symposium on the 17th June at 13:30 CEST in Room Amber 5, MiCo or online.
Join our symposium at the 60th annual ERA congress to learn about real-world clinical experience of novel therapies to manage secondary hyperparathyroidism (SHPT) and hyperphosphataemia in chronic kidney disease (CKD) patients, amongst many other interesting topics. Watch a teaser video below.
Symposium title: Ensuring a treatment continuum for CKD-MBD
Presented by an international faculty addressing the chronic kidney disease–mineral and bone disorder (CKD-MBD) disease burden to impart knowledge to strengthen your practice. There will be a keen focus on the importance of early and effective treatment of SHPT in non-dialysis CKD patients.
Can't make it this year? Sign up here to receive the symposium summary video.
Symposium details:
Date: Saturday the 17th June
Time: 13:30 – 14:30 CEST
Room: Amber 5
Venue: MiCo - Milano Convention Centre, Italy or online
Agenda:
Don't forget to come and speak to us at our CSL Vifor booth.
Click here to register for ERA 2023 and gain access to this interactive session.
Already registered? Click here to add the symposium details to your calendar.
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd., a company of the Vifor Pharma Group, is the partner of choice for renal pharmaceutical and innovative, patient-focused solutions. The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care. For more information about Vifor Pharma, please visit www.viforpharma.com
This site does not provide medical advice and may not be relied upon by any healthcare practitioner in exercising his or her professional judgement in the practice of medicine. The information provided herein is provided for general educational purposes only, and is not to be used or relied on for any diagnostic or treatment purposes. This material is not intended to represent the best or only methods or procedures appropriate for the medical situations discussed; rather the material is intended to present an approach, view, statement or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. VFMCRP makes no warranties or representations as to the site's accuracy, completeness or up-to-date information. All users agree that access to this site is at their own risk, and that neither VFMCRP any party involved in creating or delivering this site shall be liable for damages of any kind, including without limitation, any special, direct or indirect, incidental, or consequential or punitive damages (even if VFMCRP has been advised of the possibility of such damages) arising out of access to, or use of the information contained on this site, or any errors or omissions, misprints, out-of-date information, technical or pricing inaccuracies, typographical or other errors appearing on this site. This limitation includes damages to, or for any viruses that may infect your computer equipment.
© 2021 Vifor Fresenius Medical Care Renal Pharma
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd., a company of the Vifor Pharma Group, is the partner of choice for renal pharmaceutical and innovative, patient-focused solutions. The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology …
Read More
